Clariant Reports Mixed Q3 Results, Anticipates Recovery by 2025

image

Clariant Reports Mixed Q3 Results, Anticipates Recovery by 2025

In the latest earnings call, specialty chemicals company Clariant reported a slight decline in sales for the third quarter of 2024. CEO Conrad Keijzer announced sales of 991 million CHF, reflecting a 1% drop in local currency. This decline was primarily driven by a 3% volume decrease influenced by weak catalyst sales. Despite these challenges, the company anticipates a recovery in the chemicals industry by 2025 and expects an annual EBITDA margin of around 16%. Clariant also announced the nomination of Ben van Beurden as the new Chairman of the Board and reminded stakeholders of the upcoming Investor Day to be held in London.

Key Points:

  • Clariant's third-quarter sales fell 1% in local currency to 991 million CHF, with a 3% decrease in volume.
  • EBITDA declined by 13% to 139 million CHF, with a margin of 14%.
  • The company identified restructuring opportunities and expects annual savings of 6 million CHF.
  • Ben van Beurden was nominated as the new Chairman of the Board.
  • Clariant is making progress towards a 175 million CHF savings target by 2025, with 162 million CHF already achieved.
  • The company forecasts a low single-digit sales decline for 2024 and maintains guidance for a 16% EBITDA margin.
  • An Investor Day is scheduled for November 4, 2024, in London.

Company Outlook:

  • Clariant expects a recovery in the chemicals industry by 2025.
  • Manufacturing PMIs remain below 50 in most regions, excluding China.
  • A low single-digit sales decline is anticipated for 2024, with annual EBITDA margin guidance near 16%.
  • The company expects ongoing cost benefits of 33 million CHF from performance improvement initiatives.

Negative Aspects:

  • Sales in the U.S. decreased by 6%, and Asia-Pacific sales fell by 5%, with a notable 13% decline in China.
  • The Catalysts business unit faces concerns and volatility due to decreased consumer confidence in luxury markets like China.

Positive Aspects:

  • Sales in the Additives segment increased in the high teens percentage-wise, with growth seen across all regions.
  • The company is exploring larger cost-saving programs to balance inflation.
  • The long-term outlook for Catalysts remains strong due to emerging markets for green and blue ammonia and methanol applications.

Underperformance:

  • Clariant reported a decline in sales and EBITDA in Q3 2024.
  • The Catalysts segment experienced weaker demand, contributing to the overall sales decline.

Q&A Highlights:

  • The company discussed improvements in cost management and pricing within the Catalysts business unit.
  • A 1% organic volume increase occurred in Maintenance Chemicals in Q3, with low single-digit volume trends expected in Q4.
  • The reported EBITDA margin is expected to range from 17% to 18%, excluding one-time gains.

Clariant's third-quarter performance reflects broader challenges facing the chemicals industry, as the company sees a slight sales drop and a decrease in EBITDA. Nevertheless, Clariant continues to focus on cost-saving measures and performance improvement programs to navigate the current economic environment. With a solid strategy and a positive medium-term outlook, Clariant is poised for recovery and growth in the coming years, as noted by the CEO and indicated by discussions at the Investor Day in London. The nomination of Ben van Beurden as Chairman signifies a commitment to sustainability and expertise in petrochemical markets. Despite short-term challenges, Clariant's robust U.S. production infrastructure and strategic initiatives demonstrate resilience against potential market fluctuations.